iVexSol Promotes Amitabha Deb to Chief Technology Officer

Expanded role will help accelerate access to stable producer cell line technology, helping to solve lentiviral vector shortages for CGT

LEXINGTON, Mass., August 30, 2023 -- iVexSol Inc., a next-generation stable lentiviral vector manufacturing company, today announced the promotion of Amitabha Deb, Ph.D., to the position of Chief Technology Officer.

A veteran cell and gene therapy research leader with more than 30 years of experience, Amitabha will lead the application of iVexSol’s next-generation lentiviral vector (LVV) production technology using the company’s proprietary stable cell lines. He has previously served as iVexSol’s Senior Vice President of Manufacturing Science and Technology (MS&T).

“iVexSol is in the fortunate position of being able to leverage Amitabha’s unparalleled experience in producing high quality, high titer transient material to augment our highly productive stable producer cell lines,” said CEO and Co-founder Rodney Rietze, Ph.D. “Amitabha’s technical prowess in LVV production will help ensure that our technology has the maximum reach needed to solve CGT’s lentiviral vector shortage.”

Amitabha’s early research interests were focused on gene regulation and the development of therapeutic antisense oligonucleotides. After completing his postdoctoral training at Cleveland Clinic in understanding the molecular mechanisms of malignant transformation by human viruses, he transitioned to industry, where he supported the translation of a portfolio of biologics products from R&D through clinical development and on to commercial launch.

During his time at Novartis, Amitabha held a variety of leadership roles, including supporting clinical development and leading their lentiviral vector (LVV) development group in the Cell and Gene Therapy Unit, which ultimately launched Kymriah, the first cell-based gene therapy approved by the FDA. This work also resulted in the patenting of several formulations for the stabilization of LVVs.

In addition to Kymriah, Amitabha also supported the development of three other transformative medicines, Zinplava®, Rabishield®, and Cosentyx®. He has also led Technical Development teams at Bioverativ, Sanofi, Aruvant, and other startup companies focusing on diverse cell and gene therapy applications.

“I’m excited to continue to support to the iVexSol team and the CGT community that we serve with our lentiviral vector technology,” Amitabha said. “Cell and gene therapies are transformative treatments that face significant challenges as they move into mainstream medicine – and lentiviral vector supply shouldn’t be one of them. I look forward to working with our team to solve this critical issue and ultimately help bring cell and gene therapies to even more patients in need.”

To learn more about iVexSol, please visit ivexsol.com .

About iVexSol

iVexSol, Inc. is a next-generation lentiviral vector manufacturing company that transforms the way these essential gene-delivery vehicles are made. Our solution is founded on a proprietary, advanced, stable lentiviral vector production process. iVexSol’s Intelligent Manufacturing® greatly reduces the complexity, cost, and development time for these critical components, solving lentiviral vector capacity and accelerating greater access to life-changing cell and gene therapies. For more information, please visit www.ivexsol.com.

Contact: Cathryn Brown, info@ivexsol.com